Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer

A recent literature review and network meta-analysis of phase 2/3 randomised, controlled clinical trials of approved first-line tyrosine kinase inhibitors (TKIs) involving more than 4,200 patients with metastatic renal cell carcinoma (RCC) has shown that cabozantinib, sunitinib, pazopanib, and tivozanib have similar efficacy, but tivozanib’s safety profile is superior to the profiles of the other […]

read more

PARP inhibitors, vaccines and combination therapies for kidney cancer

In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]

read more

Potential new treatments for kidney cancer discussed at 2019 Kidney Cancer Research Summit

In this interview from the 2019 Kidney Cancer Research Summit and published in the journal CURE, Dr Sumanta Pal, a medical oncologist at City of Hope, California, USA discusses the expanding field of kidney cancer treatment and what this means for patients with renal cell carcinoma (RCC). During the interview, Dr Pal discusses the use […]

read more

Tivozanib in heavily pre-treated advanced kidney cancer patients

Further data from the TIVO-3 clinical trial comparing tivozanib with sorafenib in patients with advanced renal cell carcinoma (RCC), which is unresponsive to treatment (refractory), has shown that at 32.5 months, 20 patients on tivozanib remain progression free, versus 2 patients on sorafenib. This is despite there being no positive effect on overall survival (median […]

read more

Tivozanib included in new European guidelines for kidney cancer

Tivozanib has been included as a first-line treatment recommendation for advanced renal cell carcinoma (aRCC) in new European Society of Medical Oncology (ESMO) clinical practice guidelines for RCC, published last month. Tivozanib is recommended as a first-line treatment option for people with advanced clear cell RCC of good (favourable) risk or intermediate risk. Tivozanib is a potent selective vascular endothelial growth factor […]

read more

ASCO GU 2019: Tivozanib effective for refractory metastatic kidney cancer

The results from the following study were presented at the American Society for Clinical Oncology (ASCO) genitourinary (GU) conference in San Francisco in February 2019. Dr Brian Rini from the Cleveland Clinic Taussig Cancer Institute presented the results from a phase 3 clinical trial (TIVO-3) to compare the efficacy and safety of tivozanib to sorafenib in patients […]

read more

Tivozanib expected to be included in European clinical practice guidelines for advanced kidney cancer

Tivozanib is expected to be included as a first-line treatment recommendation for advanced renal cell carcinoma (RCC) in new proposed European guidelines. An outline of the new proposed European Society of Medical Oncology (ESMO) clinical practice guidelines for advanced RCC were presented at the annual ESMO 2018 Congress in Munich, Germany last week. The presentation […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

New first-line treatment option for advanced kidney cancer available on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS England and Wales. This follows a protracted appraisal process involving three committee meetings over 20 months while the process was suspended to allow the manufacturer to submit further […]

read more

Tivozanib approved in Europe for advanced kidney cancer

Tivozanib (Fotivda) has been approved by the European Commission (EC) for the treatment of patients with advanced renal cell carcinoma (RCC). Tivozanib is a potent and selective vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) developed by AVEO Pharmaceuticals, an American pharmaceutical company. The drug is specifically approved for the first line treatment […]

read more
Showing all 10 results
  TOP